1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shenzhen YHLO Biotech Co., Ltd.
  6. Summary
    688575   CNE100005204

SHENZHEN YHLO BIOTECH CO., LTD.

(688575)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-08-04
20.15 CNY   +0.95%
07/20Shenzhen YHLO Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
05/17SHENZHEN YHLO BIOTECH CO., LTD.(SHSE : 688575) added to Shanghai Stock Exchange A Share Index
CI
05/17SHENZHEN YHLO BIOTECH CO., LTD.(SHSE : 688575) added to Shanghai Stock Exchange Composite Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
19.79 19.01 19.6 19.96 20.15 Last
6517529 8234650 7829871 5089979 4440222 Volume
-1.20% -3.94% +3.10% +1.84% +0.95% Change
Estimated financial data (e)
Sales 2022 1 791 M 265 M 265 M
Net income 2022 445 M 65,8 M 65,8 M
Net Debt 2022 - - -
P/E ratio 2022 25,6x
Yield 2022 1,17%
Sales 2023 2 469 M 365 M 365 M
Net income 2023 705 M 104 M 104 M
Net Debt 2023 - - -
P/E ratio 2023 16,2x
Yield 2023 1,84%
Capitalization 11 425 M 1 690 M 1 690 M
Capi. / Sales 2022 6,38x
Capi. / Sales 2023 4,63x
Nbr of Employees 1 569
Free-Float 27,0%
More Financials
Company
Shenzhen YHLO Biotech Co Ltd is a China-based company principally engaged in the research and development, manufacture and sales of in-vitro diagnostic equipment and supporting reagents, as well as the agency sales of some non-self-produced medical device products. The Company's products are applied in autoimmunity, reproductive health, diabetes and infectious disease fields. The Company's main products include... 
More about the company
Ratings of Shenzhen YHLO Biotech Co., Ltd.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SHENZHEN YHLO BIOTECH CO., LTD.
07/20Shenzhen YHLO Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 3..
CI
05/17SHENZHEN YHLO BIOTECH CO., LTD.(SHSE : 688575) added to Shanghai Stock Exchange A Share In..
CI
05/17SHENZHEN YHLO BIOTECH CO., LTD.(SHSE : 688575) added to Shanghai Stock Exchange Composite ..
CI
05/17Certain A Shares of Shenzhen YHLO Biotech Co., Ltd. are subject to a Lock-Up Agreement ..
CI
05/04Yunkang Braves Market Turbulence with Launch of $139 Million Hong Kong IPO
MT
04/28Shenzhen YHLO Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended Ma..
CI
02/18Shenzhen YHLO Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended Decemb..
CI
02/14YHLO Biotech Bags Nearly $53 Million Supply Deal With Japan's JSR; Shares Fall 3%
MT
02/11YHLO Biotech's COVID-19 Test Kits Wins Clearance in Japan; Shares Rally 14%
MT
01/27Shenzhen YHLO Biotech Co., Ltd., Shenzhen Puhui Zhonglian Industrial Investment Co., Lt..
CI
01/26Wuhan Dgensee Medical Laboratory Co., Ltd. announced that it expects to receive CNY 1.2..
CI
2021Shenzhen YHLO Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended Sept..
CI
More news
News in other languages on SHENZHEN YHLO BIOTECH CO., LTD.
07/20Shenzhen YHLO Biotech Co., Ltd. annonce ses résultats pour le semestre clos le 30 juin ..
04/28Shenzhen YHLO Biotech Co., Ltd. annonce ses résultats pour le premier trimestre clos le..
02/18Shenzhen YHLO Biotech Co., Ltd. annonce ses résultats pour l'année complète se terminan..
More news
Chart SHENZHEN YHLO BIOTECH CO., LTD.
Duration : Period :
Shenzhen YHLO Biotech Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHENZHEN YHLO BIOTECH CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 20,15
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Yong Bo Song Chairman & General Manager
Shi Hong Pang Chief Financial Officer
Kun Hui Hu Director
Wen Ya Yang Chairman-Supervisory Board
Chun Gen Qian Director, Director-Reagent Research & Development
Sector and Competitors
1st jan.Capi. (M$)
SHENZHEN YHLO BIOTECH CO., LTD.-18.35%1 690
MASIMO CORPORATION-47.59%8 518
SHOCKWAVE MEDICAL, INC.25.13%7 987
NOVOCURE LIMITED0.72%7 920
PENUMBRA, INC.-41.94%6 321
GETINGE AB-44.19%5 869